About this trial
This study is being conducted to better understand how pancreatic cancer behaves during treatment and how we can improve methods for monitoring disease progression. The research aims to determine whether small molecules present in the blood, called miRNAs, can help doctors assess whether the treatment is working or needs adjustment. With this, we hope to make cancer monitoring less invasive and more precise, allowing patients to receive more personalized and effective treatments.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients diagnosed with metastatic PDAC;
Patients who will start treatment with FOLFIRINOX;
18 years or older;
Who agree to participate in the study by signing the Informed Consent Form;
Disqualifiers
Patients who have previously undergone chemotherapy, whether neoadjuvant, adjuvant, or any prior first-line treatment;
Patients who do not meet the minimum criteria to receive the proposed regimen, such as those with hyperbilirubinemia, those who are not candidates due to age or performance status deterioration;
Trial population
Patients diagnosed with metastatic PDAC of both sexes, aged 18 years or older, who will start treatment with FOLFIRINOX at BP - A Beneficência Portuguesa de São Paulo.
Trial design
Cohort
Prospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Response to treatment
Response to FOLFIRINOX treatment after 4 cycles of therapy.
Response to treatment
Response to FOLFIRINOX treatment after 8 cycles of therapy.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Benedito Mauro Rossi
Lead sponsor
Beneficência Portuguesa de São Paulo
Sponsor institution